Peptides DB
Research-centric peptide and protocol reference hub
Study 20 of 21Vipivotide literatureEuropean journal of nuclear medicine and molecular imaging · Observational2026

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.

ARSi did not significantly enhance tumor absorbed doses in mCRPC patients receiving [177Lu]Lu-PSMA therapies. Larger studies are needed to confirm these findings.

Read at European journal of nuclear medicine and molecular imagingAdd to compare

Where it sits

this study against the rest of the vipivotide corpus
3
Preclinical
13
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

This study evaluated the dosimetry effects of androgen receptor signaling inhibitors (ARSi) in combination with [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T radioligand therapy in 50 mCRPC patients. The absorbed doses in tumor lesions and organs-at-risk were compared between a Combination Group and a Control Group. No significant enhancement in tumor absorbed doses was observed with ARSi therapy.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24n=502026

Abstract

The authors’ words, as European journal of nuclear medicine and molecular imaging supplied them

<h4>Background</h4>Androgen receptor signaling inhibitors (ARSi) have significantly improved clinical outcomes in men with prostate cancer (PCa). Preliminary data suggest the potential for ARSi to enhance PSMA expression in patients with mCRPC. In this analysis, we present preliminary dosimetry results from mCRPC patients treated with either [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T radioligand therapy (RLT) in combination with ARSi compared to a Control Group of patients receiving [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T monotherapy.<h4>Methods</h4>This retrospective analysis was performed at a single center, including 50 patients diagnosed with mCRPC who underwent their first cycle of [<sup>177</sup>Lu]Lu-PSMA-617 (n = 37) or [<sup>177</sup>Lu]Lu-PSMA-I&T (n = 13) RLT ± concomitant ARSi treatment (abiraterone or enzalutamide). Patients were divided into a Combination Group (RLT + ARSi, n = 25) and a Control Group (RLT only, n = 25). Quantitative SPECT imaging was performed at 3 time points: 24 h (+ CT), 48 h, and 72 h post-administration of the initial cycle of RLT. Tumor lesions were segmented using the 24 h SPECT images, while organs-at-risk (kidney, spleen, liver) were delineated on the corresponding CT. Absorbed doses were calculated by applying a mono-exponential curve fit, incorporating local density scaling. Dosimetry results were evaluated separately for each radioligand.<h4>Results</h4>Overall, 148 tumor lesions were included in this analysis (median 3 lesions per patient). The median tumor absorbed dose was comparable between the Combination Group and the Control Group: [<sup>177</sup>Lu]Lu-PSMA-617 (2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq, p = 0.24) and [<sup>177</sup>Lu]Lu-PSMA-I&T (1.2 ± 1.2 Gy/GBq vs 1.2 ± 3.5 Gy/GBq, p = 0.21). Furthermore, the median absorbed dose in organs-at-risk was comparable between the two groups in [<sup>177</sup>Lu]Lu-PSMA-617: Kidneys: 0.28 ± 0.11 Gy/GBq vs 0.27 ± 0.13 Gy/GBq, p = 0.90; Spleen: 0.05 ± 0.05 Gy/GBq vs 0.06 ± 0.05 Gy/GBq, p = 0.75; Liver: 0.08 ± 0.03 Gy/GBq vs 0.07 ± 0.04 Gy/GBq, p = 0.75). A statistically significant difference was noted in kidneys and liver for [<sup>177</sup>Lu]Lu-PSMA-I&T: Kidneys: 0.21 ± 0.10 Gy/GBq vs 0.30 ± 0.08 Gy/GBq, p = 0.01; Spleen: 0.02 ± 0.02 Gy/GBq vs 0.04 ± 0.03 Gy/GBq, p = 0.20; Liver: 0.02 ± 0.01 Gy/GBq vs 0.04 ± 0.01 Gy/GBq, p = 0.01.<h4>Conclusion</h4>In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.

Background

The study investigates the potential impact of androgen receptor signaling inhibitors (ARSi) on the dosimetry of radioligand therapies in metastatic castration-resistant prostate cancer (mCRPC) patients. ARSi have previously shown to improve clinical outcomes in prostate cancer, and there is preliminary evidence suggesting they may enhance PSMA expression. This study aims to explore whether ARSi can increase the absorbed dose in tumor lesions when used with [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapies.

Methods

This retrospective analysis included 50 mCRPC patients at a single center, divided into a Combination Group (RLT + ARSi, n=25) and a Control Group (RLT only, n=25). Patients received either [177Lu]Lu-PSMA-617 (n=37) or [177Lu]Lu-PSMA-I&T (n=13). Dosimetry was assessed using quantitative SPECT imaging at 24, 48, and 72 hours post-administration. Tumor lesions and organs-at-risk were delineated, and absorbed doses were calculated using a mono-exponential curve fit.

Results

The median tumor absorbed dose was similar between the Combination and Control Groups for both radioligands: [177Lu]Lu-PSMA-617 (2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq, p=0.24) and [177Lu]Lu-PSMA-I&T (1.2 ± 1.2 Gy/GBq vs 1.2 ± 3.5 Gy/GBq, p=0.21). In organs-at-risk, significant differences were observed in kidneys and liver for [177Lu]Lu-PSMA-I&T, but not for [177Lu]Lu-PSMA-617.

Interpretation

The study found no significant enhancement in tumor absorbed doses with the addition of ARSi, suggesting that ARSi may not improve the efficacy of [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapies in terms of dosimetry. The statistically significant differences in organ doses for [177Lu]Lu-PSMA-I&T warrant further investigation. The study's limitations, including its small sample size and retrospective design, highlight the need for larger, prospective trials.

Key findings

  • 2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24
  • 1.2 ± 1.2 Gy/GBq vs 1.2 ± 3.5 Gy/GBq for [177Lu]Lu-PSMA-I&T, p=0.21
  • Kidneys: 0.28 ± 0.11 Gy/GBq vs 0.27 ± 0.13 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.90
  • Kidneys: 0.21 ± 0.10 Gy/GBq vs 0.30 ± 0.08 Gy/GBq for [177Lu]Lu-PSMA-I&T, p=0.01
  • Liver: 0.02 ± 0.01 Gy/GBq vs 0.04 ± 0.01 Gy/GBq for [177Lu]Lu-PSMA-I&T, p=0.01

Limitations

  • single-center study
  • retrospective design
  • small sample size (n=50)
  • short follow-up period
  • preliminary dosimetry results

Elsewhere in the Vipivotide corpus

BReal-world outcomes of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-I&amp;T in [&lt;sup&gt;18&lt;/sup&gt;F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.European journal of nuclear medicine and molecular imaging · 2026 · n=25 · PSA30 response in 44% of patients.HumanALutetium-177-PSMA I&amp;T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study.European journal of nuclear medicine and molecular imaging · 2026 · n=12 · MTD established at 1000 mg/m².HumanBEvaluation of [&lt;sup&gt;225&lt;/sup&gt;Ac]Ac-PSMA-617 vis-a-vis Rechallenge [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.The Prostate · 2026 · n=66 · PSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.HumanALutetium Lu 177 vipivotide tetraxetan: A literature review.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023 · Not reported in abstract.reviewBThrombotic Microangiopathy in Patients Treated with &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA Combination Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · n=766 · Cumulative renal absorbed dose ranged from 38.6 to 65.3 Gy.HumanDGuideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.BJU international · 2026 · 7.4 GBq every 6 weeks for up to six cycles.review